Development and comparison between three type of checkpoint inhibitor drug
DOI:
https://doi.org/10.54097/hset.v36i.5707Keywords:
Checkpoint inhibitor, Cancer, Immune.Abstract
In the recent years, many monoclonal antibody drugs related to the immunotherapy is taken by many cancer patients. This passage will give the information about the three common checkpoint inhibitor drugs. Information of each of drug will be divide into three parts including mechanism and structure, efficiency and strength, drawback and side-effect. Then limitation and new improvement of checkpoint inhibitor drugs of all three drugs will be introduced in the last part.
Downloads
References
Pai JA, Satpathy AT. High-throughput and single-cell T cell receptor sequencing technologies. Nat Methods. 2021;18(8):881-892. doi:10.1038/s41592-021-01201-8
Evolution of CD8+ T Cell Receptor (TCR) Engineered Therapies for the Treatment of Cancer. Cells. 2021 Sep;10(9): 2379.
Wang.XB,et al.Regulation of surface and intracellular expression of CTLA-4 on human peripheral Tcells.Scand.J.lmmunol.2001;54:453-458
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2265ef30-253e-11df-8a39-0800200c9a66
Mir T, Al-Masalmeh N, Ambreen S. Acute Pneumonitis Due to Nivolumab and Ipilimumab Combination. Am J Ther. 2020;29(1): e126-e128.
Usama M, Mir T, Fida A, et al. Ipilimumab-Induced Hypophysitis. Am J Ther. 2019;28(6): e761-e763.
Akhtari M, Waller EK, Jaye DL, et al. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother. 2009;32(3):322-4.
Boussiotis, Vassiliki A. M.D., Ph.D. Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
https://baike.baidu.com/item/PD-1/15285259
https://dailymed.nlm.nih.gov/dailymed/search.cfm?
Aslam W, Acash G, Shadchehr S, Lamb CR. Organizing Pneumonia Due to Nivolumab. Am J Ther. 2020;.
Achufusi TG, Chebaya P, Seth R. Nivolumab-Induced Adrenal Insufficiency: A Rare Side Effect of Immune Checkpoint Inhibitor Therapy. Am J Ther. 2020;.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee
Gupta R, Zaid S, Sayed A, et al. Atezolizumab Induced Myocarditis on a Background of Cardiac Amyloidosis. Am J Ther. 2019;26(6): e795-e797.
Marcoval J, Moreno-Vilchez C, Llobera-Ris C, Torrecilla-Vall-Llossera C, Penin RM. Sarcoidosis Induced by Atezolizumab Presenting with Xanthelasma Infiltration. Am J Dermatopathol. 2021; 43(12): 980-983.
Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022; 32(5): 324-333.
Haroche J, Cohen Aubart F, Mokhtari K, et al. Immune Reconstitution Syndrome After Nivolumab for Progressive Multifocal Leukoencephalopathy. Neurol., Clin. pract.. 2021;11(3): e376-e378.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
